Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 11/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233977 | 0.87 | KDM4E (0.62) | ANO1CA1CA2P2RX7KDM4E | |
| SCHEMBL8651252 | 0.86 | SHMT1 (0.55) | P2RX7HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8651766 | 0.84 | P2RX7 (0.47) | ANO1P2RX7KDM4EALDH1A1HTT | |
| SCHEMBL9926464 | 0.83 | P2RX7 (0.51) | P2RX7KDM4EPOLBHDAC3HDAC1 | |
| SCHEMBL8655125 | 0.81 | P2RX7 (0.44) | ANO1P2RX7POLBHDAC3HDAC1 | |
| SCHEMBL8559264 | 0.81 | ANO1 (0.43) | ANO1P2RX7POLBHDAC3HDAC1 | |
| SCHEMBL9926535 | 0.80 | P2RX7 (0.49) | P2RX7ALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL8654003 | 0.79 | P2RX7 (0.43) | ANO1P2RX7KDM4EALDH1A1HTT | |
| SCHEMBL9926646 | 0.79 | P2RX7 (0.48) | P2RX7HTTMAPTHDAC3HDAC1 | |
| SCHEMBL8558450 | 0.79 | ANO1 (0.42) | ANO1P2RX7KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | ANO1 4818/4885CA1 4201/4885CA2 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.